ClinicalTrials.gg
TerminatedNCT04633187RSVTxUpdated Aug 22, 2024Results posted

Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract

A Phase 2 interventional study of EDP-938 and Placebo in Respiratory Syncytial Virus Infections, sponsored by Enanta Pharmaceuticals, Inc. Terminated at 64 sites in 19 countries. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-22.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated due to a strategic business decision and not due to safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
16 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections — 1 open to participants now, 1 under way, none of them phase 3. EDP-938 · Respiratory Syncytial Virus Infections.

Enrollment
10th of 10
9 · median 81
Started
2021
with 1 other
Phase 2
4 of 10
1 open now
Registered
6th of 10
by date
Lead sponsor
10 of 10
Enanta Pharmaceuticals, Inc

Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is one of 4 in phase 2, and was the 6th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About EDP-938

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 16 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

This was a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of EDP-938 in HCT recipients with acute RSV infection and symptoms of URTI.

03

Conditions studied

  • Respiratory Syncytial Virus Infections
04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Received an HCT (within 6 months of signing ICF) or an allogeneic HCT (any time) using any conditioning regimen
  • Absolute lymphocyte count (ALC) \<500 cells/ µL in allogeneic HCT recipients. Absolute lymphocyte count (ALC) \<300 cells/ µL in autologous HCT recipients.
  • Laboratory confirmed RSV diagnosis from a respiratory sample obtained within 3 days before signing the ICF.
  • New onset of at least one of the following respiratory symptoms within 3 days before signing the ICF: nasopharyngeal discharge, nasopharyngeal congestion, sneezing, sinus congestion, sore throat, hoarseness, earache, cough, shortness of breath, respiratory wheeze, or worsening of one of these symptoms if present chronically (associated with a previously existing diagnosis [eg, chronic rhinorrhea, chronic lung disease]) in the 3 days before signing the ICF or at Screening.
  • No evidence of new abnormalities consistent with LRTI on a chest imaging (chest x-ray and/or computed tomography) performed in the 2 days before signing the ICF or at the Screening visit if there is no chest X-ray and/or computed tomography available in the 2 days before signing the ICF.
  • Oxygen saturation >95% on room air.
  • A woman of who is sexually active with a male must agree to use two effective methods of from the date of Screening until 30 days after her last dose of study drug.
  • A male subject who has not had a vasectomy and is sexually active with a woman of childbearing potential must agree to use effective contraception from the date of Screening to 90 days after his last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Admitted to the hospital primarily for a lower respiratory tract disease of any cause as determined by the Investigator.
  • Known to be concurrently infected with other respiratory viruses (eg, severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] or other coronavirus, influenza, parainfluenza, human rhinovirus, adenovirus, human metapneumovirus) within 7 days before signing the ICF, as determined by local testing.
  • viremia, bacteremia, or fungemia, or bacterial or fungal pneumonia within 2 weeks before signing the ICF that has not been adequately treated, as determined by the Investigator.
  • Known positive (HIV).
  • Any clinical manifestation resulting in .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    EDP-938

    Drug: EDP-938

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • EDP-938 800mg Dose adjustments were made for subjects taking azole antifungals.

  • DrugPlacebo

    Subjects took EDP-938 matching placebo tablets once a day orally for 21 days

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication

    Time frame: Day 1 through Day 28

Secondary outcomes

  1. Change From Baseline in RSV RNA Viral Load

    Time frame: Day 1 through Day 49

  2. Proportion of Subjects Progressing to Respiratory Failure (of Any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) or All-cause Mortality

    Time frame: Day 1 through Day 49

  3. Safety as Measured the Number of Participants With at Least One Treatment-emergent Adverse Event

    Time frame: Day 1 through Day 49

  4. Plasma PK Concentrations of EDP-938 800mg

    Time frame: Day 1 Predose and Postdose, Day 4 Predose, Day 7 Predose and Postdose, Day 11 Predose, Day 16 Predose, Day 21 Predose and Postdose

07

Results

Posted Aug 22, 2024

Participant flow

Participant flow — Overall Study
MilestoneEDP-938Placebo
Started54
Edp-938 150 mg10
Edp-938 400 mg10
Edp-938 800 mg30
Completed54
Not completed00

Outcome measures

PrimaryPercentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication
Time frame:
Day 1 through Day 28
Reported as:
Count of participants · Participants
Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication
ParticipantsEDP-938Placebo
Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication01
SecondaryChange From Baseline in RSV RNA Viral Load
Time frame:
Day 1 through Day 49
Reported as:
Mean · RSV viral load (log10 copies/mL)
Change From Baseline in RSV RNA Viral Load
RSV viral load (log10 copies/mL)EDP-938Placebo
Change From Baseline in RSV RNA Viral Load-7.072 ± 0.7738-2.221 ± 6.8552
SecondaryProportion of Subjects Progressing to Respiratory Failure (of Any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) or All-cause Mortality
Time frame:
Day 1 through Day 49
Reported as:
Count of participants · Participants
Proportion of Subjects Progressing to Respiratory Failure (of Any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) or All-cause Mortality
ParticipantsEDP-938Placebo
Proportion of Subjects Progressing to Respiratory Failure (of Any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) or All-cause Mortality00
SecondarySafety as Measured the Number of Participants With at Least One Treatment-emergent Adverse Event
Time frame:
Day 1 through Day 49
Reported as:
Count of participants · Participants
Safety as Measured the Number of Participants With at Least One Treatment-emergent Adverse Event
ParticipantsEDP-938Placebo
Safety as Measured the Number of Participants With at Least One Treatment-emergent Adverse Event53
SecondaryPlasma PK Concentrations of EDP-938 800mg
Time frame:
Day 1 Predose and Postdose, Day 4 Predose, Day 7 Predose and Postdose, Day 11 Predose, Day 16 Predose, Day 21 Predose and Postdose
Reported as:
Mean · ng/mL
Plasma PK Concentrations of EDP-938 800mg
ng/mLEDP-938
Day 1 Predose0 ± 0
Day 1 Postdose1123.33 ± 1028.899
Day 4 Predose1610.00 ± 175.784
Day 7 Predose1342.33 ± 411.554
Day 7 Postdose1394.33 ± 493.504
Day 11 Predose1176.67 ± 204.287
Day 16 Predose860.00 ± 411.887
Day 21 Predose755.33 ± 58.011
Day 21 Postdose1136.00 ± 656.195

Adverse events

Collected over Adverse event data was collected beginning on Day 1 and concluded at the End-of-Study (EOS) visit on Day 49, 28 days following the last dose of the study drug.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EDP-9380/5 (0%)4/5 (80%)5/5 (100%)
Placebo0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventEDP-938Placebo
DiarrhoeaGastrointestinal disorders1/50/4
HypertransaminasaemiaHepatobiliary disorders1/50/4
Mucosal infectionInfections and infestations1/50/4
Decreased appetiteMetabolism and nutrition disorders1/50/4
Most frequent other events
Showing 10 of 55
Most frequent other events
EventEDP-938Placebo
HypokalaemiaMetabolism and nutrition disorders2/50/4
HypomagnesaemiaMetabolism and nutrition disorders2/50/4
NauseaGastrointestinal disorders2/51/4
VomitingGastrointestinal disorders2/51/4
PyrexiaGeneral disorders2/50/4
DyspnoeaRespiratory, thoracic and mediastinal disorders2/50/4
ConjunctivitisInfections and infestations0/51/4
FolliculitisInfections and infestations0/51/4
HypervolaemiaMetabolism and nutrition disorders0/51/4
HypocalcaemiaMetabolism and nutrition disorders1/51/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)EDP-938PlaceboTotal
Mean44.4 ± 15.9844.3 ± 15.9944.3 ± 14.95
Sex: Female, Male
Sex: Female, Male(Participants)EDP-938PlaceboTotal
Female224
Male325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EDP-938PlaceboTotal
Hispanic or Latino101
Not Hispanic or Latino448
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EDP-938PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White538
More than one race000
Unknown or Not Reported011
08

Study locations

64 sites
  • Augusta University Medical Center
    Augusta, Georgia 30912, United States
  • Fundación Favaloro
    Buenos Aires, Ciudad Autónoma De BuenosAires C1093AAS, Argentina
  • Instituto Fides
    La Plata, Ciudad Autónoma De BuenosAires 483 5051, Argentina
  • Sanatorio Allende S.A.
    Córdoba, Cordoba X5000JHQ, Argentina
  • Hospital Britanico de Buenos Aires
    Buenos Aires, C1280AEB, Argentina
  • UZ Antwerpen
    Edegem, Antwerpen 2650, Belgium
  • Institute Jules Bordet
    Anderlecht, Brussels 1070, Belgium
  • Hôpital de Jolimont
    La Louvière, 7100, Belgium
  • Chronos Pesquisa Clínica
    Brasília, Distrito Federal 72145-450, Brazil
  • Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
    Porto Alegre, Rio Grande Do Sul 90035, Brazil
  • Hospital Universitário de Santa Maria
    Santa Maria, Rio Grande Do Sul 97105-900, Brazil
  • Fundação PIO XII
    Barretos, Sao Paulo 14784, Brazil
  • Hospital Alemão Oswaldo Cruz
    São Paulo, Sao Paulo 01323-903, Brazil
  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
    São Paulo, Sao Paulo 05403000, Brazil
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Queen Mary Hospital
    Hong Kong, Hong Kong, China
  • Hospital Pablo Tobón Uribe
    Medellín, Colombia
  • CHU de Nice
    Nice, Alpes-Maritimes 06202, France
  • Hôtel Dieu -Angers
    Angers, Maine-et-Loire 49933, France
  • Hôpital Claude Huriez
    Lille, Nord 59037, France
  • Hopital Cote de Nacre
    Caen, 14000, France
  • Hôpital Saint Antoine
    Paris, 75012, France
  • Attikon University General Hospital
    Athens, Greece
  • Evangelismos General Hospital of Athens
    Athens, Greece
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Sheba Medical Center
    Ramat Gan, 52621, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia - INCIPIT - PIN
    Brescia, Lombardia 25123, Italy
  • Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona-Umberto I G.M. Lancisi G. Salesi
    Ancona, Marche 60020, Italy
  • A.O.U. Maggiore della Carità
    Novara, Piemonte 28100, Italy
  • Azienda ULSS 8 "Berica" - Ospedale San Bortolo
    Vicenza, Veneto 36100, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Firenze, 50134, Italy
  • Fondazione Policlinico Universitario A Gemelli
    Roma, 00168, Italy
  • Chungnam National University Hospital
    Daejeon, 301-721, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • Gachon University Gil Medical Center
    Ulsan, 682714, Korea, Republic of
  • Instituto Nacional de Cancerologia
    Mexico City, 14080, Mexico
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Oddzial w Gliwi
    Gliwice, Slaskie, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdańsk, Poland
  • Albert Alberts Stem Cell Transplant Centre
    Pretoria, Gauteng 0044, South Africa
  • FCRN Clinical Trial Centre (Pty) Ldt
    Vereeniging, Gauteng 1935, South Africa
  • WITS Clinical Research Site
    Johannesburg, South Africa
  • Hospital Universitario Son Espases
    Palma De Mallorca, Baleares 07010, Spain
  • ICO l'Hospitalet - Hospital Duran i Reynals
    L'Hospitalet De Llobregat, Barcelona 08908, Spain
  • Hospital de San Pedro de Alcantara
    Cáceres, Caceres 10003, Spain
  • Hospital Universitario Virgen de La Arrixaca
    El Palmar, Murcia 30120, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario Virgen de Las Nieves
    Granada, 18014, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz - PPDS
    Madrid, 28046, Spain
  • Hospital General Universitario Morales Meseguer
    Murcia, 30008, Spain
  • Hospital Regional Universitario de Malaga - Hospital General
    Málaga, 29010, Spain
  • Hospital Universitario Virgen del Rocio - PPDS
    Sevilla, 41013, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46026, Spain
  • Changhua Christian Medical Foundation Changhua Christian Hospital
    Changhua, 50006, Taiwan
  • Taipei Veterans General Hospital
    Taipei City, Taiwan
  • Ege Universitesi Tip Fakultesi Hastanesi
    Bornova, Izmir, Turkey
  • Namik Kemal University
    Tekirdağ, Tekirdag, Turkey
  • Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi
    Samsun, Turkey
  • Imperial College
    London, W12 0HS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in May 2023, 22 months.

Results were first posted in Aug 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2020
First posted
Nov 18, 2020
StartActual
Jul 7, 2021
Primary completionActual
May 31, 2023
CompletionActual
May 31, 2023
Results first posted
Aug 22, 2024
Last update
Aug 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04633187
Responsible party
Sponsor
First posted
Nov 18, 2020
Start date
Jul 7, 2021
Primary completion
May 31, 2023
Completion
May 31, 2023
Results posted
Aug 22, 2024
Last update
Aug 22, 2024

Study contacts

Enanta Pharmaceuticals, Inc
study director · Enanta Pharmaceuticals, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP-938

Start the discussion